Vivani Medical (VANI) News
NASDAQ: VANIHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
1.14+0.05 (+4.59%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VANI news summary
We found 6 recent headlines mentioning Vivani Medical (VANI): 1 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, VANI is up 4.59% at $1.14. The most recent story, "Vivani Medical Announces Private Placement Equity Financing", was published by GlobeNewswire on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Vivani Medical headlines
- Vivani Medical Announces Private Placement Equity FinancingVivani Medical announces $5.1M private placement equity financingGlobeNewswire
- Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight SubjectsVivani Phase 1 study reports no nausea or vomiting and comparable weight loss to Wegovy controls with once- or twice-yearly GLP-1 implant.GlobeNewswire
- Vivani's Q3 Loss Widens Mildly To $7 Mln; Data For GLP-1 Implant Expected Later This Week(RTTNews) - Vivani Medical Inc. (VANI), a clinical-stage biopharmaceutical company, on Tuesday reported financial results for the third quarter, noting a slightly wider loss due to increased expenses.NasdaqNVO, VANI, HEI.A
- Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business UpdateTop-line results for SLIM-1™, the first-in-human Phase 1 trial of NPM-139, Vivani's miniature, ultra-long-acting semaglutide implant under development for chronic weight management, are anticipated…GlobeNewswire
- Vivani Medical Announces Participation in Upcoming Investor ConferencesVivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting drug implants utilizing its proprietary NanoPortal™…GlobeNewswire
- Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal(RTTNews) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech and pharmaceutical…NasdaqABBV, AZN, CMMB, GMAB